PRMT5 and adenoid cystic carcinoma: Similarly, single-cell RNA sequencing of adenoid cystic carcinoma organoids revealed PRMT5 upregulation correlated with MYB/MYC genes—a finding that not only uncovered novel biomarkers but also validated PRMT5 inhibitors as a viable therapeutic strategy currently in phase I clinical trials [67].